Kineta, Inc. (KANT)
OTCMKTS
· Delayed Price · Currency is USD
0.3361
0.00 (0.00%)
Jul 2, 2025, 4:00 PM EDT
Kineta Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
4.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 5.44M | 3.49M | 178.65% |
| Dec 31, 2022 | 1.95M | -7.14M | -78.52% |
| Dec 31, 2021 | 9.09M | -1.40M | -13.32% |
| Dec 31, 2020 | 10.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| Elite Pharmaceuticals | 84.04M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Kineta News
- 7 months ago - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT - PRNewsWire
- 7 months ago - KANT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kineta, Inc. Is Fair to Shareholders - Business Wire
- 8 months ago - Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) - GlobeNewsWire
- 10 months ago - Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - GlobeNewsWire
- 10 months ago - Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1 - GlobeNewsWire
- 10 months ago - Kineta, Inc Transitioning from Nasdaq to OTC Markets - GlobeNewsWire